Anti-proliferative actions of 2-decylamino-5,8-dimethoxy-1,4-naphthoquinone in vascular smooth muscle cells

Biochemical and Biophysical Research Communications

Volumn 411, Issue 1, 2011, Pages 213-218

  Lee, Jung Jin ^a   Zhang, Wei Yun ^a   Yi, Hyoseok ^a   Kim, Yohan ^a   Kim, In Su ^a   Shen, Gui Nan ^a   Song, Gyu Yong ^a   Myung, Chang Seon ^a  

^a Chungnam National University   (South Korea)

Author keywords

Cell cycle; Naphthoquinone; Restenosis; Vascular smooth muscle cell

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 1,4 NAPHTHOQUINONE DERIVATIVE; 2 DECYLAMINO 5,8 DIMETHOXY 1,4 NAPHTHOQUINONE; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN E; CYCLINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOLIPASE C GAMMA1; PLATELET DERIVED GROWTH FACTOR B; PROTEIN KINASE B; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; DRUG MECHANISM; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR SMOOTH MUSCLE;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; CORONARY RESTENOSIS; G0 PHASE; G1 PHASE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NAPHTHOQUINONES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RETINOBLASTOMA PROTEIN;

EID: 79960562425     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.06.145     Document Type: Article

References (28)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362:801-809.
2. Ross R. Mechanisms of atherosclerosis - a review. Adv. Nephrol. Necker Hosp. 1990, 19:79-86.
3. Dzau V.J., Braun-Dullaeus R.C., Sedding D.G. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat. Med. 2002, 8:1249-1256.
4. Schwartz R.S., Holmes D.R., Topol E.J. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J. Am. Coll. Cardiol. 1992, 20:1284-1293.
5. Strauss B.H., Chisholm R.J., Keeley F.W., Gotlieb A.I., Logan R.A., Armstrong P.W. Extracellular matrix remodeling after balloon angioplasty injury in a rabbit model of restenosis. Circ. Res. 1994, 75:650-658.
6. Sachinidis A., Locher R., Hoppe J., Vetter W. The platelet-derived growth factor isomers, PDGF-AA PDGF-AB and PDGF-BB, induce contraction of vascular smooth muscle cells by different intracellular mechanisms. FEBS Lett. 1990, 275:95-98.
7. Bornfeldt K.E., Raines E.W., Graves L.M., Skinner M.P., Krebs E.G., Ross R. Platelet-derivated growth factor. Distinct signal transduction pathways associated with migration versus proliferation. Ann. NY Acad. Sci. 1995, 766:416-430.
8. Ahn H.Y., Hadizadeh K.R., Seul C., Yun Y.P., Vetter H., Sachinidis A. Epigallocathechin-3 gallate selectively inhibits the PDGF-BB-induced intracellular signaling transduction pathway in vascular smooth muscle cells and inhibits transformation of sis-transfected NIH 3T3 fibroblasts and human glioblastoma cells (A172). Mol. Biol. Cell 1999, 10:1093-1104.
9. Blenis J. Signal transduction via the MAP kinases: proceed at your own RSK. Proc. Natl. Acad. Sci. USA 1993, 90:5889-5892.
10. Heldin C.H., Ostman A., Ronnstrand L. Signal transduction via platelet-derived growth factor receptors. Biochim. Biophys. Acta 1998, 1378:F79-F113.
11. Braun-Dullaeus R.C., Mann M.J., Sedding D.G., Sherwood S.W., Von der Leyen H.E., Dzau V.J. Cell cycle-dependent regulation of smooth muscle cell activation. Arterioscler. Thromb. Vasc. Biol. 2004, 24:845-850.
12. Braun-Dullaeus R.C., Mann M.J., Sedding D.G., Sherwood S.W., Von der leyen H.E., Dzau V.J. Cell cycle-dependent regulation of smooth muscle cell activation. Arterioscler. Thromb. Vasc. Biol. 2004, 24:845-850.
13. Van de Werf F., Diaz R., Paolasso E. The RAPT investigators, Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT) Circ. 1994, 89:588-595.
14. Sherr C.J., Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999, 13:1501-1512.
15. Chen X., Yang L., Oppenheim J.J., Howard M.Z. Cellular pharmacology studies of shikonin derivatives. Phytother. Res. 2002, 16:199-209.
16. Yuk D.Y., Ryu C.K., Hong J.T., Chung K.H., Kang W.S., Kim Y., Yoo H.S., Lee M.K., Lee C.K., Yun Y.P. Antithrombotic and antiplatelet activities of 2-chloro-3-[4-(ethylcarboxy)-phenyl]-amino-1,4-naphthoquinone (NQ12) a newly synthesized 1,4-naphthoquinone derivative. Biochem. Pharmacol. 2000, 60:1001-1008.
17. Chamley J.H., Campbell G.R., McConnell J.D., Groschel-Stewart U. Comparison of vascular smooth muscle cells from adult, human monkey and rabbit in primary culture and in subculture. Cell Tissue Res. 1977, 177:503-522.
18. Kim J.H., Jin Y.R., Park B.S., Kim T.J., Kim S.Y., Lim Y., Hong J.T., Yoo H.S., Yun Y.P. Luteolin prevents PDGF-BB-induced proliferation of vascular smooth muscle cells by inhibition of PDGF beta-receptor phosphorylation. Biochem. Pharmacol. 2005, 69:1715-1721.
19. Lee J.J., Yu J.Y., Zhang W.Y., Kim T.J., Lim Y., Kwon J.S., Kim D.W., Myung C.S., Yun Y.P. Inhibitory effect of fenofibrate on neointima hyperplasia via G0/G1 arrest of cell proliferation. Eur. J. Pharmacol. 2011, 650:342-349.
20. Sachinidis A., Locher R., Vetter W., Tatje D., Hoppe J. Different effects of platelet-derived growth factor isoforms on rat vascular smooth muscle cells. J. Biol. Chem. 1990, 265:10238-10243.
21. Kim T.J., Lim Y., Kim D.W., Kwon J.S., Son J.H., Jin Y.R., Son D.J., Jung J.C., Avery M.A., Hong J.T., Yun Y.P. Epothilone D a microtubule-stabilizing compound inhibits neointimal hyperplasia after rat carotid artery injury by cell cycle arrest via regulation of G1-checkpoint proteins. Vascul. Pharmacol. 2007, 47:229-237.
22. Graf K., Xi X.P., Yang D., Fleck E., Hsueh W.A., Law R.E. Mitogen-activated protein kinase activation is involved in platelet-derived growth factor-directed migration by vascular smooth muscle cells. Hypertension 1997, 29:334-339.
23. Martin A., Odajima J., Hunt S.L., Dubus P., Ortega S., Malumbres M., Barbacid M. Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1). Cancer Cell 2005, 7:591-598.
24. Jirawatnotai S., Aziyu A., Osmundson E.C., Moons D.S., Zou X., Kineman R.D., Kiyokawa H. Cdk4 is indispensable for postnatal proliferation of the anterior pituitary. J. Biol. Chem. 2004, 279:51100-51106.
25. Sherr C.J. Cancer cell cycles. Science 1996, 274:1672-1677.
26. Akiyama T., Ohuchi T., Sumida S., Matsumoto K., Toyoshima K. Phosphorylation of the retinoblastoma protein by cdk2. Proc. Natl. Acad. Sci. USA 1992, 89:7900-7904.
27. Connell-Crowley L., Elledge S.J., Harper J.W. G1 cyclin-dependent kinases are sufficient to initiate DNA synthesis in quiescent human fibroblasts. Curr. Biol. 1998, 8:65-68.
28. Tomita H., Osanai T., Toki T., Maeda N., Murakami R., Chen Z., Yamabe H., Osawa H., Yasujima M., Okumura K. Roxithromycin is an inhibitor of human coronary artery smooth muscle cells proliferation: a potential ability to prevent coronary heart disease. Atherosclerosis 2005, 182:87-95.